Abstracts tagged "Comorbidity"

Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 0215 • ACR Convergence 2020
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Ernest Choy¹, Iain McInnes², John Cush³, Jacob Aelion⁴, William Rigby⁵, Yanna Song⁶, Sebastian Meerwein⁷, John Liu⁸, Nasser Khan⁸, Jessica Suboticki⁸ and Alexander Cohen⁹, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Texas Southwestern Medical School, Dallas, TX, ⁴Arthritis Clinic PLLC, Jackson, ⁵Dartmouth College, Norwichi, VT, ⁶AbbVie Inc., North Chicago,, IL, ⁷Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
Abstract Number: 1044 • ACR Convergence 2020
Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
Lara Sanchez-Bilbao¹, David Martinez-Lopez², Inigo Gonzalez-Mazon³, Maria José García-García⁴, Montserrat Rivero-Tirado⁴, Beatriz Castro⁴, Javier Crespo⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in…
Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Hanna Källmark¹, Birgitta Gullstrand², Johanna Nagel³, Jon Einarsson¹, Göran Jönsson⁴, Fredrik Kahn⁵, Robin Kahn⁶, Anders Bangtsson², Tomas Bergström⁷ and Meliha Kapetanovic¹, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden and Skåne University Hospital Sweden., Lund, Sweden, ²Department of Rheumatology, Clinical Sciences, Lund University Sweden, Lund, Sweden, ³Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ⁵Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden; Wallenberg Centre of Molecular Medicine, Lund University, Lund, Sweden, ⁷Department of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 1134 • ACR Convergence 2020
Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases
Katherine Wysham¹, Joshua Baker², Kristin Wipfler³, Sarah Lieber⁴, Sebastian Sattui⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹VA Puget Sound/University of Washington, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Hospital for Special Surgery, New York, NY, ⁵University of California, San Francisco, Novato, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Frailty is associated with poor health outcomes in the general population, and recent studies have highlighted its importance in rheumatic musculoskeletal diseases (RMDs). Prior…
Abstract Number: 0320 • ACR Convergence 2020
Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Tal Gazitt¹, Muhanad Abu Elhija¹, Amir Haddad¹, Idit Lavi¹, Muna Elias¹ and Devy Zisman¹, ¹Carmel Hospital, Haifa, Israel
Background/Purpose: To assess the implementation of the “Treat-to-Target” (T2T) concept using validated composite disease activity scores in daily management of psoriatic arthritis (PsA).Methods: A retrospective…
Abstract Number: 1181 • ACR Convergence 2020
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Courtney O'Brien¹, Aman Kugasia², Anna Gorfin³, Lauren Klebek³, Joshlean Fair³ and Joel Block¹, ¹Rush University, Chicago, IL, ²Arthritis Clinic of Cypress and Katy, PA, Katy, TX, ³Rush University, Chicago
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…
Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Maria Elisa Acosta¹, Olga Compán², Sonia Pastor¹, Guadalupe Manzano Canabal¹, Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Olga Martinez Gonzalez⁵, Ana Isabel Turrión¹, Javier Del Pino-Montes¹ and Carlos Montilla Morales¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, ´Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
Abstract Number: 1219 • ACR Convergence 2020
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Piero Ruscitti¹, Onorina Berardicurti¹, Paola Cipriani¹ and Roberto Giacomelli¹, ¹University of L'Aquila, L'Aquila, Italy
Background/Purpose: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets by using biologic DMARDs designed for rheumatoid arthritis (RA), and IL-1…
Abstract Number: 0419 • ACR Convergence 2020
Survival and Prevalent Comorbidities in Polymyalgia Rheumatica
Carl Turesson¹, Ankita Sharma², Charlotta Fors², Jan Åke Nilsson³, Aladdin Mohammad⁴ and Ulf Bergström², ¹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: There is limited information on mortality in patients with polymyalgia rheumatica (PMR), and on prevalent comorbidity at the time of diagnosis of PMR. The…
Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Gillian Fitzgerald¹, George Tomlinson², Steve Ramkissoon³, Sophie Wojcik⁴, Robert Inman⁵ and Nigil Haroon⁶, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴UHN, Montreal, QC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
Abstract Number: 1325 • ACR Convergence 2020
Monoclonal Gammopathy in Psoriatic Arthritis
Vanessa Ocampo¹ and Dafna Gladman², ¹University of Toronto, University Health Network, Psoriatic Arthritis Research Program, Toronto, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma disorder, defined by the presence of a serum monoclonal protein (M-protein) at…
Abstract Number: 0550 • ACR Convergence 2020
Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index
Jared Vanderbleek¹, Justin Owensby¹, Alex Mccannaly¹, Lang Chen¹, Bryant England², Jeffrey R Curtis³ and Huifeng Yun³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Identifying and accurately classifying comorbid conditions in large, real-world data sources is crucial for cohort establishment and confounder adjustment. However, the ability to conduct…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].